Article Text

Download PDFPDF
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma
  1. Jonathan A. Ledermann, MD, FRCP*,
  2. Daniela Luvero, MD*,
  3. Aaron Shafer, MD,
  4. Dennis O’Connor, MD,
  5. Giorgia Mangili, MD§,
  6. Michael Friedlander, MBChB, FRACP, PhD,
  7. Jacobus Pfisterer, MD,
  8. Mansoor R. Mirza, MD#,
  9. Jae-Weon Kim, MD**,
  10. Jerome Alexandre, MD,,
  11. Amit Oza, MD, FRPCPC, MBBs, and
  12. Jubilee Brown, MD§§
  1. *UCL Cancer Institute and UCL Hospitals, London UK;
  2. Hartford Hospital, Hartford, CT;
  3. University of Louisville School of Medicine, Louisville, KY;
  4. §IRCCS San Raffaele Hospital, Milan, Italy;
  5. The Prince of Wales Hospital Randwick, New South Wales, Australia;
  6. Gynecologic Oncology Center, Kiel, Germany;
  7. #Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark;
  8. **Seoul National University College of Medicine, Seoul, Korea;
  9. ††Paris Descartes University, Cochin–Hôtel Dieu, Paris;
  10. ‡‡Princess Margaret Hospital, Toronto, Canada; and
  11. §§MD Anderson Cancer Centre, Houston, TX.
  1. Address correspondence and reprint requests to Jonathan A. Ledermann, BSc, MD, FRCP, UCL Cancer Institute, Cancer Research UK & UCL Cancer Trials Centre, 90 Tottenham Court Road, London W1T 4TJ, United Kingdom. E-mail: j.ledermann{at}


Abstract Mucinous carcinomas of the ovary can be primary or metastatic in origin. Improvements in the pathological diagnosis have increased the ability to distinguish between primary and metastatic ovarian cancers and shown that primary mucinous carcinomas are a rare subtype of ovarian cancer. Most tumors are diagnosed at an early stage, and the prognosis after surgery is good. Advanced or recurrent mucinous carcinoma of the ovary responds poorly to current cytotoxic treatments, and the prognosis is poor. Here, we review the guidelines for surgery and the results of treatment of advanced and recurrent disease. Chemotherapy with platinum and paclitaxel is currently used to treat advanced disease, but the effect of these drugs is modest, and new treatments are needed.

  • Mucinous ovarian cancer
  • Mucinous tumor

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.